Sorrento Therapeutics Inc. (SRNE)’s Financial Results Comparing With Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI)

Sorrento Therapeutics Inc. (NASDAQ:SRNE) and Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), both competing one another are Biotechnology companies. We will contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sorrento Therapeutics Inc. 34.67M 8.04 105.32M -0.95 0.00
Spectrum Pharmaceuticals Inc. 109.33M 10.27 120.01M -0.60 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Sorrento Therapeutics Inc. and Spectrum Pharmaceuticals Inc.

Profitability

Table 2 provides us the return on equity, return on assets and net margins of both companies.

Net Margins Return on Equity Return on Assets
Sorrento Therapeutics Inc. -303.78% -46.3% -22.1%
Spectrum Pharmaceuticals Inc. -109.77% 0% 0%

Volatility and Risk

Sorrento Therapeutics Inc. has a 2.43 beta, while its volatility is 143.00% which is more volatile than S&P 500. Competitively, Spectrum Pharmaceuticals Inc.’s 170.00% volatility makes it more volatile than S&P 500, because of the 2.7 beta.

Liquidity

The Current Ratio and a Quick Ratio of Sorrento Therapeutics Inc. are 1.8 and 1.8. Competitively, Spectrum Pharmaceuticals Inc. has 2.9 and 2.9 for Current and Quick Ratio. Spectrum Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Sorrento Therapeutics Inc.

Analyst Recommendations

Sorrento Therapeutics Inc. and Spectrum Pharmaceuticals Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sorrento Therapeutics Inc. 0 0 0 0.00
Spectrum Pharmaceuticals Inc. 0 0 3 3.00

Meanwhile, Spectrum Pharmaceuticals Inc.’s average price target is $30, while its potential upside is 191.83%.

Insider and Institutional Ownership

Sorrento Therapeutics Inc. and Spectrum Pharmaceuticals Inc. has shares held by institutional investors as follows: 26% and 82%. Insiders held roughly 30.07% of Sorrento Therapeutics Inc.’s shares. Competitively, insiders own roughly 1.5% of Spectrum Pharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sorrento Therapeutics Inc. -6.82% -0.49% -41.76% -63.06% -72.85% -14.58%
Spectrum Pharmaceuticals Inc. -8.02% -2.77% -21.14% -55.15% -47.79% 24.46%

For the past year Sorrento Therapeutics Inc. has -14.58% weaker performance while Spectrum Pharmaceuticals Inc. has 24.46% stronger performance.

Summary

On 10 of the 11 factors Spectrum Pharmaceuticals Inc. beats Sorrento Therapeutics Inc.

Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It develops therapeutic products for the treatment of auto-immune, inflammatory, neurodegenerative, and infectious diseases. The company offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain at end-stage disease. Its preclinical human therapeutic antibodies include antibody drug conjugates, bispecific approaches, and T-Cell Receptor, as well as Chimeric Antigen Receptor-T Cell (CAR-T) for adoptive cellular immunotherapy for the treatment of solid and liquid tumors. It is also involved in the development of T-007, an anti-CD38 CAR-T cellular therapy for the treatment of multiple myeloma, as well as for additional potential indications, such as amyloidosis and graft-versus-host disease; and T-009, an anti-CD123 CAR-T cellular therapy for the treatment of acute myelogenous leukemia. The company has license and collaboration agreement with Les Laboratoires Servier for the development, manufacture, and commercialization of products using its human immuno-oncology anti-PD-1 mAb STI-A1110. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-HodgkinÂ’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.